Clinical Trial Registries: Why Transparency Matters
Before the FDA Amendments Act of 2007, much of clinical research operated behind a curtain. There was no requirement for clinical trials to be registered or to have their results publicly reported. Trials with positive results got published in medical journals. Trials with negative or null results often never saw the light of day. Researchers estimate that nearly half of all clinical trials went unpublished, which created a dangerously incomplete picture of how well a drug actually works.
This video from Clarity Clinical Solutions walks through how public registries changed that, and how anyone can use them to find information about clinical trials.
What the FDA Amendments Act changed
The FDA Amendments Act of 2007 (FDAAA) was a landmark law for clinical trial transparency. It required the registration of all controlled clinical trials of FDA-regulated drugs and devices, mandated the submission of summary results within 12 months of trial completion, and established enforcement mechanisms where non-compliant sponsors can face civil penalties.
It also expanded the role of ClinicalTrials.gov as the official public registry. The FDA's drug development process pages explain how the agency oversees clinical trials and what the FDAAA registration requirements mean for sponsors (FDA: The Drug Development Process). The law made trial registration and results reporting the rule, not the exception.
What ClinicalTrials.gov is
ClinicalTrials.gov is a free public database maintained by the U.S. National Library of Medicine at the National Institutes of Health. It is the largest and most widely used clinical trial registry in the world, containing over 470,000 registered trials from more than 220 countries.
Each trial receives a unique NCT number. The database covers all phases of research, from phase 1 through phase 4 (ClinicalTrials.gov).
Who has to register
Under FDAAA, trials of FDA-regulated drugs, biologics, and devices must register. That includes phase 2 through phase 4 studies and trials conducted under an investigational new drug or investigational device exemption application.
The International Committee of Medical Journal Editors goes further, requiring prospective registration before the first patient is enrolled as a condition of publication in major medical journals. That rule matters because it pushes researchers to register early, before results exist.
What a registration entry includes
A clinical trial registration includes detailed information about the study:
- The study title, purpose, and design, including primary and secondary endpoints
- Eligibility criteria describing who can participate
- The interventions being studied, including drug dosage and comparator
- The sponsor and investigators conducting the trial
- The recruitment status
Result summaries must include participant flow, baseline data, outcomes, and adverse events.
How the process works
Sponsors create a protocol registration system account. A study record is drafted and submitted for quality control review. The National Library of Medicine reviews and releases the record with an NCT number.
Critically, the record must be submitted within 21 days of enrolling the first participant. This is prospective registration: the trial is registered before it starts, not after it finishes.
Results submission
FDAAA requires summary results to be submitted within 12 months of the trial's primary completion date. What must be reported includes:
- Participant flow, showing how many completed each study arm
- Baseline characteristics of enrolled participants
- Primary and secondary outcome measures with statistical analysis
- Serious adverse events along with other adverse event data
How registries fight publication bias
Publication bias happens when studies with positive results are more likely to be published than studies with negative or null results. That is dangerous because doctors make treatment decisions based on an incomplete evidence base.
Meta-analyses overestimate treatment effects when negative studies are missing. Patients may receive treatments that appear effective but actually are not. And research resources get wasted confirming approaches that are already known not to work.
Registries are one of the most powerful tools against publication bias. Every trial is documented up front, so you can see what was planned even if it was never published. Results submission is mandatory, not left to the discretion of investigators. Outcome measures are pre-specified, which prevents selective outcome reporting. Anyone can search and find studies that would otherwise be invisible, and researchers can detect missing trials when results are overdue.
A global network
The World Health Organization runs the International Clinical Trials Registry Platform, or ICTRP, which connects 17 primary registries worldwide. These registries include ClinicalTrials.gov from the United States, the EU Clinical Trials Register, ISRCTN from the United Kingdom, GCTR from China, CTRI from India, and JAPIC CTI from Japan (WHO ICTRP).
Together these registries create a global network of clinical trial transparency.
How to search it yourself
Anyone can search ClinicalTrials.gov using a simple search interface. You can search by condition, drug, location, sponsor, or NCT number. You can filter by phase, status, age group, gender, and study type. Results show study details, a location map, and results if available. Clinical data is available for download and through an API for researchers.
This makes clinical trial information genuinely accessible to everyone, not just researchers.
Who benefits
- Patients can find trials they may qualify for and discuss them with their doctors.
- Healthcare providers make informed treatment recommendations based on the full evidence base.
- Journalists and advocates hold the medical system accountable.
- Researchers avoid duplicating studies and build on existing knowledge.
- Regulators monitor the landscape of medical research globally.
The bottom line
The FDA Amendments Act of 2007 made trial registration and results submission the law, not an option. Anyone can search ClinicalTrials.gov to find trials and their results. Registries combat publication bias by making all trials visible regardless of outcome, and a global network of 17 primary registries is connected through the WHO ICTRP.
Transparency in clinical trials is not just about good science. It is about trust, accountability, and ultimately better health outcomes for everyone.
This article is based on the Clarity Clinical Solutions video "Clinical Trial Registries: Why Transparency Matters." Watch it here: Clinical Trial Registries: Why Transparency Matters
References
- Clarity Clinical Solutions — "Clinical Trial Registries: Why Transparency Matters" (video). https://www.youtube.com/watch?v=-BqEV2eZZ6w
- ClinicalTrials.gov — the official U.S. clinical trial registry. https://clinicaltrials.gov/
- FDA — The Drug Development Process. https://www.fda.gov/drugs/development-approval-process-drugs
- WHO — International Clinical Trials Registry Platform (ICTRP). https://www.who.int/clinical-trials-registry-platform